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Abstract Our recent studies have suggested that sphingosine, 
an endogenous protein kinase C (PKC) inhibitor, may mediate 
apoptosis induced by a phorbol ester (PMA) in human 
promyelocytic leukemia HL-60 cells |Ohta et al. Cancer Res. 
1995;55:691-697], and that the apoptotic induction by both 
PMA and sphingosine is accompanied by down-regulation of bcl-
2, a gene which acts to prevent apoptotic cell death [Sakakura et 
al. FEBS Lett. 1996;397:177-180]. In this study, we examined 
the sphingosine-induced apoptosis of the androgen-independent 
human prostatic carcinoma cell line DU-145, which expresses 
bcl-Xi, and Bax but not bcl-2, and found that treatment of DU-
145 cells with sphingosine suppressed bcl-XL in both mRNA and 
protein levels but did not change bax expression at all. In 
contrast, in apoptotic cells treated with a PKC inhibitor, 
staurosporine, no effect on bcl-XL or bax expression was 
observed. The initial metabolites of sphingosine in the cells, 
ceramide and sphingosine 1-phosphate, failed to induce apopto-
sis. These results indicate that, in DU-145 cells, sphingosine, but 
not its metabolites, induces apoptosis through down-regulation of 
bcl-XL, independently of PKC inhibition. Our present results, 
together with previous observations, strongly suggest that 
apoptosis regulatory genes differ according to cell type and 
apoptosis induction through sphingosine is accompanied by 
inhibition of either bcl-2 or bcl-XL activity in these cells. 
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1. Introduction 
Sphingomyelin hydrolysis products, ceramide, sphingosine 
and their metabolites, play important roles in the regulation 
of cell growth, differentiation and apoptosis [1-4]. Intracellu-
lar levels of sphingosine, an endogenous PKC inhibitor [5,6], 
increased in HL-60 cells during the PMA-induced apoptotic 
process [7,8]. Similarly, it was observed that treatments of 
human neutrophils [9] and cardiac myocytes [10] with tumor 
necrosis factor-oc (TNF-oe) induced apoptosis and enhanced 
concomitantly the endogenous sphingosine concentration. In 
these studies, exogenously added sphingosine also induced 
apoptosis in these cells and it was proposed that sphingosine, 
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produced in response to apoptotic stimuli, functions as an 
endogenous inducer of apoptosis. Recently, we reported that 
sphingosine and its ^-methylated derivative, A^TV-dimethyl-
sphingosine, is able to induce apoptosis in cancer cells of 
both hematopoietic and solid tumor origin ([11,12]; Sakakura, 
Sweeney, Shirahama, Solca, Kohno, Hakomori, Fisher, Iga-
rashi, submitted). Sphingosine did not, however, induce apop-
tosis in normal epithelial cells such as HUVECs or rat mesan-
gial cells, but did induce apoptosis in their transformed 
counterparts ([11]; Sakakura, Sweeney, Shirahama, Solca, 
Kohno, Hakomori, Fisher, Igarashi, submitted). 
The apoptotic process is encoded by an endogenous pro-
gram, and deregulation is considered to be involved in human 
disease states including acquired immunodeficiency syndrome, 
neurogenerative disorders and cancer [13,14]. Cell death by 
apoptosis occurs when a cell activates an internally encoded 
suicide program as a result of either extrinsic or intrinsic 
signals. The bcl-2 proto-oncogene has been identified as a 
molecule which counters a variety of apoptotic stimuli [15-
17], suggesting that it might be a central death repressor in the 
apoptotic pathway. However, bcl-2 has failed to protect some 
hematopoietic cells from apoptosis induced by cytokine dep-
rivation or receptor-mediated signaling [18]. Recently, a new 
bcl-2-related gene, bcl-X, has been identified [19,20]. Alterna-
tive splicing produces two species of mRNA, named bcl-XL 
and bcl-Xg. Bcl-XL acts as a cell death repressor, while bcl-Xg 
acts as a cell death promoter, and both genes appear to be 
involved in some bcl-2-independent apoptosis [18,19]. Another 
gene implicated in the apoptotic pathway is bax [21-23]. Bax 
is able to homodimerize as well as heterodimerize with bcl-2 
or bcl-XL. When in excess, bax counters the ability of bcl-2 or 
bcl-XL to prevent apoptotic cell death. We previously re-
ported that sphingosine down-regulates bcl-2 expression in 
mRNA as well as protein levels, resulting in apoptosis induc-
tion in HL-60 cells, but that bcl-Xi, expression level is not 
affected by sphingosine treatment [8]. Since apoptosis is 
known to be regulated through both bcl-2-dependent and 
-independent (including those involving bcl-XL) pathways, in 
different cell types [18,19], the effects of sphingosine on bcl-XL 
in these cells were unclear. 
To address this issue, we chose androgen-independent hu-
man prostatic carcinoma DU-145 cells which express bcl-XL 
but not bcl-2 at the protein level. We show here that sphin-
gosine, but not its metabolites, induced apoptosis in these cells 
by down-regulation of bcl-XL, most probably independently 
of PKC inhibition. 
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2. Materials and methods 
2.1. Cell culture 
Human prostatic carcinoma DU-145 cells were purchased from 
American Type Culture Collection (ATCC, Rockville, MD), and 
maintained in DMEM medium containing 10% heat-inactivated fetal 
bovine serum supplemented with 2 mM L-glutamine. 
2.2. Sphingolipids and other chemicals 
Sph was purchased from Sigma (St. Louis, MO). Sphingosine-1-
phosphate [24] and C2-ceramide [25] were synthesized as previously 
described. All sphingolipids were dissolved in 50% ethanol and were 
utilized by proper dilution. Staurosporine (Sigma, St. Louis, MO) was 
dissolved in DMSO. 
2.3. Measurement of apoptosis by flow cytometry 
Cultured cells were treated with various agents including Sph as 
described above. Apoptotic cells were quantitatively evaluated by 
flow cytometry as described previously [12]. After centrifugation, the 
resultant cell pellet was resuspended in 0.3 ml hypotonie fluorochrome 
solution containing 50 ug/ml propidium iodide, 0.1% sodium citrate 
and 0.1% Triton X-100. The fluorescence of individual nuclei was 
analyzed using an EPICS flow cytometer (Coulter Electronics, Hia-
leah, FL). 
2.4. Analysis of DNA fragmentation 
DNA fragmentation was analyzed by agarose gel electrophoresis as 
described in our previous paper [8], using DU-145 cells treated for 15 h 
at 37°C with one of the following: 15 (xM Sph, C2-ceramide, or 
sphingosine-1-phosphate, or 100 nM staurosporine. 
2.5. Northern blot analysis 
Total RNA was prepared by the acid guanidine thiocyanate-phe-
nol-chloroform method [7], For Northern blot analysis, 20 ug of total 
RNA was denatured with glyoxal, subjected to 1.2% agarose gel elec-
trophoresis, and transferred to a Hybond nylon membrane (Amer-
sham, St. Louis, MO). The membrane was probed with a 875 bp 
bcl-XL cDNA probe (nucleotides 96-875), which was labeled with 
[cc-32P]dCTP by the random oligonucleotide priming method. Human 
ß-actin cDNA (Clontech, Palo Alto, CA) probe was used as a control. 
2.6. Western blot analysis 
After treatment with each reagent, the cells were washed 3 times 
with PBS(—) and lysed in Laemmli's sample buffer [26]. Proteins were 
separated by SDS-polyacrylamide gel electrophoresis on a 12% gel 
and were electrophoretically transferred to a nitrocellulose membrane 
(Bio-Rad, Hercules, CA). After blocking with 5% skimmed milk at 
room temperature for 2 h, blots were allowed to react with rabbit 
polyclonal antibody to human bcl-XL (L-19) or mouse bax (P-19) 
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1/100 dilution in 
PBS(—) with 5% skimmed milk for 2 h at room temperature. The 
blot was incubated with horseradish peroxidase-conjugated goat 
anti-rabbit IgG (Jackson Laboratories, West Grove, PA) at 1/100 
dilution in PBS(—) with 5% skimmed milk at room temperature for 
2 h, and visualized with ECL kit (Amersham, St. Louis, MO). 
3. Results and discussion 
The aim of the present study was to examine the effects of 
sphingosine on apoptotic induction in androgen-independent 
prostatic carcinoma DU-145 cells and its regulatory effect on 
bcl-2-related genes. Flow cytometric analysis showed that 
sphingosine induces apoptosis in these cells in both a dose-
and a time-dependent manner (Fig. 1). Exogenously added 
sphingosine is metabolically converted to sphingosine-1-P or 
ceramide [12] which is thought to be an endogenous mediator 
for apoptotic signaling induced by radiation or TNF-a in 
leukemic cells such as HL-60 and U-937 cells [27-29]. Apop-
totic induction was usually observed with exogenously added 
short-chain cell permeable ceramides, such as C2- or C6-
ceramide, but not with long-chain natural ceramides [4,11]. 
Fig. 1. Percentage of apoptotic cells after treatment for 2, 6 or 15 h 
with ethanol vehicle (0.1%, control) (o), 5 (J.M (o) or 15 uM sphin-
gosine (•), as determined by flow cytometry. 
However, neither sphingosine-1-phosphate nor cell permeable 
ceramide, C2-ceramide, caused apoptosis in DU-145 cells 
under the present experimental conditions (Fig. 2). The apop-
totic induction by sphingosine was also confirmed by internu-
cleosomal DNA fragmentation which is a hallmark of apop-
tosis (data not shown) [30]. The protein kinase C inhibitor, 
staurosporine, also induced apoptosis, although the number 
of apoptotic cells seen was much less in the cells treated with 
staurosporine than in those with sphingosine (Fig. 2). 
Sphingosine has been proposed as an endogenous mediator 
for apoptosis [7,9], but the mechanism involved has not been 
established. We have previously shown that apoptosis result-
ing from PMA-induced terminal differentiation of human leu-
kemic HL-60 cells was accompanied by an increase in intra-
cellular sphingosine levels and down-regulation of bcl-2 in 
both mRNA and protein levels [8]. Exogenously added sphin-
gosine did not induce cellular differentiation in these cells, but 
did induce apoptosis with down-regulation of bcl-2 expres-
sion. However, neither treatment with PMA nor sphingosine 
affected the expression levels of the death promoter, bax and 
the death repressor, bcl-XL. We suggest that down-regulation 
of bcl-2 by sphingosine might be responsible for apoptosis 
resulting from PMA-induced terminal differentiation of HL-
60 cells. Also, these results suggest that only bcl-2 was respon-
sible for apoptotic induction in HL-60 cells and that down-
regulation of bcl-2 was enough to induce apoptosis, although 
HL-60 cells express another apoptosis repressor gene, bcl-XL. 
This possibility may be supported by the observation that 
TNF-a as well as ceramide, an endogenous mediator for 
apoptosis caused by TNF-a, also induces apoptosis in HL-
60 cells with down-regulation of bcl-2 but without any 
changes in bcl-XL expression [29]. 
In the present experiment using DU-145 cells, sphingosine 
induced apoptosis with a concomitant decrease of bcl-XL ex-
pression in both mRNA and protein levels, but without any 
changes in bax expression (Fig. 3). These changes in the apop-
tosis-related genes produce a decreased ratio of bcl-XL/bax 
heterodimers to bax/bax homodimers, a situation suggested 
to be sufficient to induce apoptosis [21,23]. From the present 
results and those of our previous studies [8], we conclude that 
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Fig. 2. Percentage of apoptotic cells after treatment for 15 h with 
ethanol (control), 15 |J,M sphingosine, 15 |iM C2-ceramide, 15 |J,M 
sphingosine-1-phosphate (Sph-l-P) and 100 nM staurosporine, as 
determined by flow cytometry. Data are the means of two independ-
ent experiments with similar values. 
apoptosis regulatory genes differ according to cell type and 
that sphingosine induces apoptosis by inhibiting either bcl-2 
or bcl-XL activity. In apoptosis induced by the PKC inhibitor 
staurosporine, neither bcl-XL nor bax expression was 
changed, indicating that the apoptotic mechanism induced 
by PKC inhibition differs from that induced by sphingosine. 
A key signal transducer, p21Ras, is known to regulate the 
differentiation and proliferation of eukaryotic cells [31,32]. It 
has also been demonstrated that p21Ras interacts with the 
serine/threonine kinase Raf-1, which in turn regulates the ac-
tivity of a kinase cascade that includes MEK and mitogen-
activated protein kinases (MAPK) [33,34]. Recently, it was 
reported that Ras-generating signals lead not only toward 
cell growth, but can also initiate apoptosis, depending upon 
the state of other cellular signaling mediators such as bcl-2 
and PKC [35,36]. Ras-induced apoptosis was triggered after 
suppression of cellular PKC activity and was blocked by bcl-
2. We previously showed that sphingosine suppressed MAPK 
in solid tumor cells, resulting in the induction of apoptosis 
and suggesting that sphingosine-induced apoptotic signaling 
may be related to Ras/Raf-1/MAPK cascade (Sakakura, 
Sweeney, Shirahama, Solca, Kohno, Hakomori, Fisher, Igara-
shi, submitted). 
Normal prostatic epithelium and prostatic carcinoma cells 
proliferate in response to androgen stimulation [37]. This an-
drogen dependence has been the basis of androgen ablation 
therapy for prostatic carcinomas. However, most prostatic 
carcinomas become resistant to androgen ablation therapy 
within 2 years through androgen receptor mutation or some 
other unknown mechanism [38,39]. Androgen-independent 
prostatic carcinomas are also resistant to anti-cancer agents, 
which is thought to be a major cause of the failure of prostatic 
carcinoma treatment. Because many anti-cancer agents have 
been found to suppress tumor growth by inducing apoptosis 
[40], it is important to understand the relationship between 
androgen independence in prostatic carcinoma cells and the 
expression of apoptosis-related genes. 
Recently, it was shown by RT-PCR that apoptosis repres-
B 
Fig. 3. Immunoblotting analysis. A: Western blot analysis. Lysates from control cells (0.1% ethanol) or cells treated with 15 |xM sphingosine, 
or 100 nM staurosporine for 2, 6 or 15 h were immunoblotted with anti-human-bcl-2 antibody or anti-human-bcl-XL antibody. B: Northern 
blot analysis of bcl-XL mRNA. Total RNA (20 |xg) from cells treated for 15 h with or without 15 |J,M sphingosine was subjected to 1.2% agar-
ose gel electrophoresis and probed with bcl-XL cDNA probe. Human ß-actin cDNA probe was used as a control. 
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sor genes including bcl-2 and bcl-XL were expressed in D U -
145 cells, but anti-sense bcl-2 oligonucleotides failed to en-
hance the apoptosis caused by staurosporine [41]. However, 
we detected bcl-XL protein but not bcl-2 protein in DU-145 
cells, suggesting that anti-sense bcl-2 oligonucleotides would 
not be effective in these cells. A similar expression in both bcl-
2 and bcl-XL proteins was also observed in another androgen-
independent prostatic carcinoma cell line, PC-3, in which 
sphingosine also induced apoptosis with down-regulation of 
bcl-XL (data not shown). These results suggest that bcl-XL 
may be an apoptosis repressor gene in androgen-independent 
prostatic carcinoma cells, and that sphingosine or its deriva-
tives such as A^Af-dimethylsphingosine might be effective in 
the therapeutic treatment of this disease. 
Acknowledgements: This work was supported by grants from the 
Ministry of Education, Science and Culture of Japan. 
References 
[1] Y.A. Hannun, R.M. Bell, Science 243 (1989) 500-507. 
[2] A.H. Merrill, V. Stevens, Biochim Biophys Acta 1010 (1989) 
131-139. 
[3] S. Hakomori, J Biol Chem 265 (1990) 18713-18716. 
[4] Y.A. Hannun, C M . Linardic, Biochim Biophs Acta 1154 (1993) 
223-236. 
[5] Y. Igarashi, S. Hakomori, T. Toyokuni, B. Dean, S. Fujita, M. 
Sugimoto, T. Ogawa, K. El-Ghendy, E. Racker, Biochemistry 28 
(1989) 6796-6800. 
[6] A.H. Merrill Jr., S. Nimkar, D. Menaldino, Y.A. Hannun, C. 
Loomis, R.M. Bell, S.R. Tyagi, J.D. Lambeth, V.L. Stevens, R. 
Hunter, D.C. Liotta, Biochemistry 28 (1989) 3138-3145. 
[7] H. Ohta, E.A. Sweeney, A. Masamune, Y. Yatomi, S. Hakomori, 
Y. Igarashi, Cancer Res 55 (1995) 691-697. 
[8] C. Sakakura, E.A. Sweeney, T. Shirahama, S. Hakomori, Y. 
Igarashi, FEBS Lett 379 (1996) 177-180. 
[9] H. Ohta, Y. Yatomi, E.A. Sweeney, S. Hakomori, Y. Igarashi, 
FEBS Lett 355 (1994) 267-270. 
[10] K.A. Krown, M.T. Page, C. Nguyen, D. Zechner, V. Guteirrez, 
K.L. Comstock, C.C. Glembotski, P.J.E. Quintana, R.A. Sabba-
dini, J Clin Invest 98 (1996) 2854-2865. 
[11] E.A. Sweeney, C. Sakakura, T. Shirahama, S. Masamune, H. 
Ohta, S. Hakomori, Y. Igarashi, Int J Cancer 66 (1996) 358-366. 
[12] T. Shirahama, E.A. Sweeney, C. Sakakura, K. Nishiyama, S. 
Akiyama, S. Hakomori, Y. Igarashi, Clin Cancer Res 3 (1997) 
257-264. 
[13] J.C. Reed, J Cell Biol 124 (1994) 1-5. 
[14 
[is: 
tie: 
in: 
[is: 
[i9: 
[20 
[21 
[22 
[23: 
[24 
[25: 
pe: 
[27: 
[28 
[29: 
[30 
[31 
[32 
[33: 
[34 
[35: 
[36 
[37 
[38: 
[39: 
[40 
[41 
C.B. Tompson, Science 267 (1995) 1456-1462. 
Y. Tsujimoto, J. Gorham, J. Cossman, E. Jaffe, C M . Croce, 
Science 229 (1985) 1390-1393. 
D.L. Vaux, I.L. Weissman, S.K. Kim, Science 258 (1992) 1955-
1957. 
I. Garcia, I. Martinou, Y. Tsujimoto, J.C. Martinou, Science 258 
(1992) 302-304. 
G. Nunez, L. London, D. Hockenbery, M. Alexander, J.P. 
Mckearn, S.J. Korsmeyer, J Immunol 144 (1990) 3602-3610. 
L.H. Boise, M. Gonzalez-Garcia, C E . Postema, L. Ding, T. 
Lindsten, L.L. Turka, X. Mao, G. Nunez, C.B. Thompson, 
Cell 74 (1993) 597-608. 
A.J. Minn, L.H. Boise, G.B. Thompson, J Biol Chem 271 (1996) 
6306-6312. 
Z.N. Oitvai, C.L. Milliman, S.J. Korsmeyer, Cell 74 (1993) 609-
619. 
C. Sakakura, E.A. Sweeney, T. Shirahama, Y. Igarashi, S. Ha-
komori, H. Nakatani, T. Tsujimoto, T. Imanishi, M. Ohgaki, T. 
Ohyama, J. Yamazaki, A. Hagiwara, T. Yamaguchi, K. Sawaki, 
T. Takahashi, Int J Cancer 67 (1996) 101-105. 
E. Yang, J. Zha, L.H. Boise, C.B. Thompson, S.J. Korsmeyer, 
Cell 80 (1995) 285-291. 
P.P. Van Veldhoven, R.J. Foglesong, R.M. Bell, J Lipid Res 30 
(1989)611-616. 
R.R. Vannam, N.S. Radin, Biochim Biophys Acta 573 (1979) 73-
82. 
U.K. Laemmli, Nature 227 (1970) 680-685. 
K.A. Dressler, S. Mathias, R.N. Kolesnick, Science 255 (1992) 
1715-1718. 
R. Kolesnick, D.W. Golde, Cell 77 (1994) 325-328. 
M. Chen, J. Quintans, Z. Fuks, C Thompson, D.W. Kufe, R.R. 
Weichselbaum, Cancer Res 55 (1995) 991-994. 
S.J. Martin, D.R. Green, T.G. Cotter, Trends Biochem Sei 19 
(1994) 26-30. 
J. Downward, BioEssays 14 (1992) 177-184. 
M.S. Marshall, Trends Biochem Sei 18 (1993) 250-254. 
A.B. Vojtek, S.M. Hollenberg, J.A. Cooper, Cell 74 (1993) 205-
214. 
B. Hallberg, S.I. Rayter, J. Downward, J Biol Chem 269 (1994) 
3913-3916. 
C.Y. Chen, D.V. Faller, Oncogene 11 (1995) 1487-1498. 
C.Y. Chen, D.V. Faller, J Biol Chem 271 (1996) 2376-2379. 
C. Huggins, C.V. Hodges, Cancer Res 1 (1941) 293-297. 
A.A. Sinha, C E . Blackard, U.S. Seal, Cancer (Philadelphia) 40 
(1977) 2836-2850. 
J.P. Gaddipati, D.G. Mcleod, H.B. Heidenberg, I.A. Sesterhenn, 
M.J. Finger, J.W. Moul, S. Srivastava, Cancer Res 54 (1994) 
2861-2864. 
D.E. Fisher, Cell 78 (1994) 539-542. 
H. Zhang, T. Hoang, B. Saeed, S.-C Ng, Prostate 29 (1996) 69-
76. 
